Meisoindigo, an active compound of a Chinese anti-leukemia medicine, has been effectively used in the treatment of chronic myelogenous leukemia (CML). Increasing evidences have demonstrated that angiogenesis is an important pathobiologic feature of CML. The anti-angiogenesis effect of meisoindigo on CML is unknown.
 
[CML]
A group of CMLHope.Com
Subscribe: [EMAIL PROTECTED]
Web Site: http://groups.cmlhope.com 

Reply via email to